Literature DB >> 27904736

The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.

Valentín Ortíz-Maldonado1, Pablo Mozas1, Julio Delgado2.   

Abstract

B-cell lymphoma 2 (BCL2)-type proteins are key regulators of the intrinsic or mitochondrial pathway for apoptosis. Since escape from apoptosis is one the main 'hallmarks of cancer', BCL2 inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Multiple clinical trials have shown efficacy of these agents in patients with relapsed/refractory disease with a favorable toxicity profile. Moreover, some clinical trials indicate that combination with monoclonal antibodies and other novel agents may enhance their effect.

Entities:  

Keywords:  B-cell lymphoma 2; BH3-mimetics; chronic lymphocytic leukemia

Year:  2016        PMID： 27904736      PMCID： PMC5089327          DOI： 10.1177/2040620716671313

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  40 in total

1.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

Authors:  S Kitada; J Andersen; S Akar; J M Zapata; S Takayama; S Krajewski; H G Wang; X Zhang; F Bullrich; C M Croce; K Rai; J Hines; J C Reed
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

2.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Authors:  Joel D Leverson; Darren C Phillips; Michael J Mitten; Erwin R Boghaert; Dolores Diaz; Stephen K Tahir; Lisa D Belmont; Paul Nimmer; Yu Xiao; Xiaoju Max Ma; Kym N Lowes; Peter Kovar; Jun Chen; Sha Jin; Morey Smith; John Xue; Haichao Zhang; Anatol Oleksijew; Terrance J Magoc; Kedar S Vaidya; Daniel H Albert; Jacqueline M Tarrant; Nghi La; Le Wang; Zhi-Fu Tao; Michael D Wendt; Deepak Sampath; Saul H Rosenberg; Chris Tse; David C S Huang; Wayne J Fairbrother; Steven W Elmore; Andrew J Souers
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Woyach; Engin Bojnik; Amy S Ruppert; Matthew R Stefanovski; Virginia M Goettl; Kelly A Smucker; Lisa L Smith; Jason A Dubovsky; William H Towns; Jessica MacMurray; Bonnie K Harrington; Melanie E Davis; Stefania Gobessi; Luca Laurenti; Betty Y Chang; Joseph J Buggy; Dimitar G Efremov; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

Review 5.  New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.

Authors:  Farrukh T Awan; John C Byrd
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

6.  Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

Authors:  Clara Campàs; Ana M Cosialls; Montserrat Barragán; Daniel Iglesias-Serret; Antonio F Santidrián; Llorenç Coll-Mulet; Mercè de Frias; Alicia Domingo; Gabriel Pons; Joan Gil
Journal:  Exp Hematol       Date:  2006-12       Impact factor: 3.084

7.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Authors:  David Chiron; Maurizio Di Liberto; Peter Martin; Xiangao Huang; Jeff Sharman; Pedro Blecua; Susan Mathew; Priyanka Vijay; Ken Eng; Siraj Ali; Amy Johnson; Betty Chang; Scott Ely; Olivier Elemento; Christopher E Mason; John P Leonard; Selina Chen-Kiang
Journal:  Cancer Discov       Date:  2014-07-31       Impact factor: 39.397

8.  5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

Authors:  Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander B Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; John Gribben; Loretta M Itri; Kanti R Rai
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Authors:  G S Choudhary; S Al-Harbi; S Mazumder; B T Hill; M R Smith; J Bodo; E D Hsi; A Almasan
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469
View more
  1 in total

1.  p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.

Authors:  Laura Patrussi; Nagaja Capitani; Cristina Ulivieri; Noemi Manganaro; Massimo Granai; Francesca Cattaneo; Anna Kabanova; Lucia Mundo; Stefania Gobessi; Federica Frezzato; Andrea Visentin; Francesca Finetti; Pier Giuseppe Pelicci; Mario M D'Elios; Livio Trentin; Gianpietro Semenzato; Lorenzo Leoncini; Dimitar G Efremov; Cosima T Baldari
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.